PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
P/B ratio for PepGen Inc. (PEPG)
P/B ratio as of 2023: 1.49
According to PepGen Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.49. At the end of 2022 the company had a P/B ratio of 1.76.
P/B ratio history for PepGen Inc. from 2019 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 1.49 |
| 2022 | 1.76 |
| 2021 | 2.17 |
| 2020 | 29.53 |
| 2019 | 74.64 |